Evaluation and management of women with BRCA1/2 mutations

ONCOLOGY

Volumn 19, Issue 11, 2005, Pages 1451-1459

  Peshkin, Beth N ^a   Isaacs, Claudine ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST TUMOR; FEMALE; GENETIC COUNSELING; GENETICS; HUMAN; MUTATION; OVARIECTOMY; OVARY TUMOR; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; HUMANS; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION BEHAVIOR; TAMOXIFEN;

EID: 33644875778     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Phillips KA: Current perspectives on BRCA1- and BRCA2-associated breast cancers. Intern Med J 31:349-356, 2001.
2. Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665-676, 2004.
3. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998.
4. Garber JE, Offit K: Hereditary cancer predisposition syndromes. J Clin Oncol 23:276-292, 2005.
5. Eng C, Hampel H, de la Chapelle A: Genetic testing for cancer predisposition. Ann Rev Med 52:371-400, 2001.
6. Breast Cancer Information Core. Available at http://research.nhgri.nih.gov/bic/. Accessed August 24, 2005.
7. Unger MA, Nathanson KL, Calzone K, et al: Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet 67:841-850, 2000.
8. BRACAnalysis Technical Specifications. Myriad Genetic Laboratories, Updated August 29, 2005. Available at www.myriadtests.com/provider/doc/ tech_specs_brac.pdf. Accessed August 29, 2005.
9. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997.
10. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002.
11. Kauff ND, Perez-Segura P, Robson ME, et al: Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 39:611-614, 2002.
12. National Comprehensive Cancer Network: Genetic/familial high-risk assessment: Breast and ovarian. Clinical Practice Guidelines in Oncology, version 1.2005. Available at www.nccn.org/professionals/ physician_gls/PDF/genetics_screening.pdf. Accessed August 24, 2005.
13. Hampel H, Sweet K, Westman JA, et al: Referral for cancer genetics consultation: A review and compilation of risk assessment criteria. J Med Genet 41:81-91, 2004.
14. Myriad Genetic Laboratories: Mutation prevalence tables for BRCA1/2 genes. Available at www.myriadtests.com/provider/mutprev.htm. Accessed August 24, 2005.
15. Marroni F, Aretini P, D'Andrea E, et al: Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 41:278-285, 2004.
16. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al: BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701-2712, 2002.
17. CancerGene. Available at www.utsouthwestern.edu/utsw/cda/dept47829/files/ 65844.html. Accessed August 24, 2005.
18. Peshkin BN, DeMarco TA, Brogan BM, et al: BRCA1/2 testing: Complex themes in result interpretation. J Clin Oncol 19:2555-2565, 2001.
19. Trepanier A, Ahrens M, McKinnon W, et al: Genetic cancer risk assessment and counseling: Recommendations of the National Society of Genetic Counselors. J Genet Counsel 13:83-114, 2004.
20. Braithwaite D, Emery J, Walter F, et al: Psychological impact of genetic counseling for familial cancer: A systematic review and meta-analysis. J Natl Cancer Inst 96:122-133, 2004.
21. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002.
22. Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692-695, 1994.
23. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003.
24. King MC, Marks JH, Mandell JB and the New York Breast Cancer Study Group: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003.
25. Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316, 1999.
26. Metcalfe KA, Lynch HT, Ghadirian P, et al: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335, 2004.
27. Robson M, Svahn T, McCormick B, et al: Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 orBRCA2. Cancer 103:44-51, 2005.
28. Dawson LA, Chow E, Goss PE: Evolving perspectives in contralateral breast cancer. Eur J Cancer 34:2000-2009, 1998.
29. Metcalfe KA, Lynch HT, Ghadirian P, et al: The risks of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96:222-226, 2005.
30. Liede A, Karlan BY, Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J Clin Oncol 22:735-742, 2004.
31. Ries LAG, Eisner MP, Kosary CL, et al (eds): SEER Cancer Statistics Review, 1975-2000. Bethesda, Md, National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2002. Accessed August 24, 2005.
32. Narod SA: Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2:113-123, 2002.
33. Thompson D, Easton D, Breast Cancer Linkage Consortium: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68:410-419, 2001.
34. Al-Saffar M, Foulkes WD: Hereditary ovarian cancer resulting from a non-ovarian cancer cluster region (OCCR) BRCA2 mutation: Is the OCCR useful clinically? J Med Genet 39:e68, 2002.
35. Welcsh PL, King MC: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10:705-713, 2001.
36. Jernstrom H, Lubinski J, Lynch HT, et al: Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96:1094-1098, 2004.
37. Hartge P, Chatterjee N, Wacholder S, et al: Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history. Epidemiol 13:255-261, 2002.
38. Narod SA, Dube MP, Klijn J, et al: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773-1779, 2002.
39. Narod SA, Brunet J-S, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 356:1876-1881, 2000.
40. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002.
41. King MC, Wieand S, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251-2256, 2001.
42. Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-22, 2002.
43. Nkondjock A, Ghadirian P: Epidemiology of breast cancer among BRCA mutation carriers: An overview. Cancer Lett 205:1-8, 2004.
44. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325, 2004.
45. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004.
46. Scheuer L, Kauff N, Robson M, et al: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260-1268, 2002.
47. Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609-1615, 2002.
48. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005.
49. Dunn BK, Wickerham DL, Ford LG: Prevention of hormone-related cancers: Breast cancer. J Clin Oncol 23:357-367, 2005.
50. Rebbeck TR, Friebel T, Lynch HT, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22:1055-1062, 2004.
51. Meijers-Heijboer H, van Geel B, van Putten WL, et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159-164, 2001.
52. Wainberg S, Husted J: Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 13:1989-1995, 2004.
53. Schwartz MD, Lerman C, Brogan B, et al: Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 22:1823-1829, 2004.
54. Jacobs IJ, Skates SJ, MacDonald N, et al: Screening for ovarian cancer: A pilot randomised controlled trial. Lancet 353:1207-1210, 1999.
55. Liede A, Karlan BY, Baldwin RL, et al: Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20:1570-1577, 2002.
56. Karlan BY: Defining cancer risks for BRCA germline mutation carriers: Implications for surgical prophylaxis (editorial). Gynecol Oncol 92:519-520, 2004.
57. Modugno F, Ovarian Cancer and High-Risk Women Symposium Presenters: Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecol Oncol 91:15-31, 2003.
58. Powell CB, Kenley E, Chen LM, et al: Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127-132, 2005.
59. Garber JE, Hartman AR: Prophylactic oophorectomy and hormone replacement therapy: Protection at what price? (editorial) J Clin Oncol 22:978-980, 2004.